Anti-Mouse osteopontin/SPP1 Antibody (100D3) is an anti-mouse osteopontin/SPP1 IgG2c monoclonal antibody. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can reverse the inhibition of osteopontin (OPN) on T cells and enhance cytotoxic T lymphocyte (CTL) killing ability. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can improve dentin density. Anti-Mouse osteopontin/SPP1 Antibody (100D3) can be used for researches on cancer and dental related conditions such as colon cancer. The recommend isotype control of Anti-Mouse osteopontin/SPP1 Antibody (100D3): Mouse IgG2c kappa, Isotype Control [1] [2].
In Vivo, Anti-Mouse osteopontin/SPP1 Antibody (100D3) (200 μg, s.c., once every 3 days, for 14 days) significantly reduces lung metastatic nodules in Balb/c mice bearing CT26 tumors[1]. Anti-Mouse osteopontin/SPP1 Antibody (100D3) (200 μg, s.c., twice a week, from day 7 to day 60) effectively improves dentin density in BALB/C mice[2].
In Vitro, Anti-Mouse osteopontin/SPP1 Antibody (100D3) (3 days) can reverse the inhibition of osteopontin (OPN) on T cell proliferation[1]. Anti-Mouse osteopontin/SPP1 Antibody (100D3) (24 h) significantly enhances the killing efficiency of cytotoxic T lymphocyte (CTL) against CT26[1].
References:
[1]. Klement JD, et al. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel). 2021 Feb 28;13(5):1006.
[2]. Mohamed FF, et al. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice. Bone. 2023 Nov;176:116886.
In Vivo, Anti-Mouse osteopontin/SPP1 Antibody (100D3) (200 μg, s.c., once every 3 days, for 14 days) significantly reduces lung metastatic nodules in Balb/c mice bearing CT26 tumors[1]. Anti-Mouse osteopontin/SPP1 Antibody (100D3) (200 μg, s.c., twice a week, from day 7 to day 60) effectively improves dentin density in BALB/C mice[2].
In Vitro, Anti-Mouse osteopontin/SPP1 Antibody (100D3) (3 days) can reverse the inhibition of osteopontin (OPN) on T cell proliferation[1]. Anti-Mouse osteopontin/SPP1 Antibody (100D3) (24 h) significantly enhances the killing efficiency of cytotoxic T lymphocyte (CTL) against CT26[1].
References:
[1]. Klement JD, et al. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel). 2021 Feb 28;13(5):1006.
[2]. Mohamed FF, et al. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice. Bone. 2023 Nov;176:116886.